Search Result

Results for "

BNP-7787

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Drug Derivative (2) Drug Metabolite (1) Isotope-Labeled Compounds (1) Reference Standards (1) SOD (2)
By Research Areas:	Cancer (3) Endocrinology (3) Metabolic Disease (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1022

Dimesna 1 Publications Verification BNP-7787	Drug Derivative	Endocrinology Cancer
Dimesna (BNP-7787), the disulfide form of Mesna (HY-13679), is a platinum-related toxicity protective agent. Dimesna converts to Mesna, which in turn inactivates toxic platinum substances. Dimesna does not interfere with the antitumor activity of platinum compounds. Dimesna does not affect the antiproliferative effects of Cisplatin (HY-17394) or Carboplatin (HY-17393). Dimesna counteracts Cisplatin-induced nephrotoxicity. Dimesna exerts selective protective effects on the kidneys. Dimesna can be used in studies related to ovarian cancer and Cisplatin-induced nephrotoxicity .

HY-W017960

Diludine Et-HE; 1,4-DHP	SOD	Endocrinology
Diludine (BNP-7787) is an orally effective feed additive. Diludine reduces the activity of G6PD and increases the level of superoxide dismutase (SOD). Diludine reduces the mutagenic effect of environmental pollutants, protects parental reproductive systems and improves offspring quality. Diludine is mainly applied during the transition period of dairy cows to increase milk yield and milk fat content, and improve health status during parturition. Diludine can be used in animal feeding research .

HY-B1022A

Dimesna free acid BNP-7787 free acid	Drug Derivative	Endocrinology Cancer
Dimesna (BNP-7787) free acid, the disulfide form of Mesna (HY-13679), is a platinum-related toxicity protective agent. Dimesna free acid converts to Mesna, which in turn inactivates toxic platinum substances. Dimesna free acid does not interfere with the antitumor activity of platinum compounds. Dimesna free acid does not affect the antiproliferative effects of Cisplatin (HY-17394) or Carboplatin (HY-17393). Dimesna free acid counteracts Cisplatin-induced nephrotoxicity. Dimesna free acid exerts selective protective effects on the kidneys. Dimesna free acid can be used in studies related to ovarian cancer and Cisplatin-induced nephrotoxicity .

HY-W017960R

Diludine (Standard) Et-HE (Standard); 1,4-DHP (Standard)	SOD Reference Standards	Metabolic Disease
Diludine (Standard) is the analytical standard of Diludine (HY-W017960). This product is intended for research and analytical applications. Diludine (BNP-7787) is an orally effective feed additive. Diludine reduces the activity of G6PD and increases the level of superoxide dismutase (SOD). Diludine reduces the mutagenic effect of environmental pollutants, protects parental reproductive systems and improves offspring quality. Diludine is mainly applied during the transition period of dairy cows to increase milk yield and milk fat content, and improve health status during parturition. Diludine can be used in animal feeding research .

HY-W699643

Dimesna-d8 BNP-7787-d₈	Isotope-Labeled Compounds Drug Metabolite	Cancer
Dimesna-d₈ (BNP-7787-d₈) is the deuterium labeled Dimesna (HY-B1022). Dimesna combined with anticancer chemotherapeutic agents to reduce nephrotoxicity.

Dimesna-d8
Dimesna-d₈ (BNP-7787-d₈) is the deuterium labeled Dimesna (HY-B1022). Dimesna combined with anticancer chemotherapeutic agents to reduce nephrotoxicity.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.